Notícias

Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

Novo Nordisk A/S (NYSE:NVO) was at the center of media coverage as it sued rival weight loss drug manufacturer Eli Lilly on Tuesday. The firm claimed that Lilly had run misleading advertisements about its weight loss drug when it came to touting their superior performance over Novo Nordisk A/S (NYSE:NVO)’s products. It claimed that Lilly […]

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State S

Eli Lilly just won FDA clearance for an oral GLP-1 that targets over one billion potential patients worldwide, and the stock has barely moved. Here is whether that disconnect signals a buying opportunity or a trap.

Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs.

Novo Nordisk (CPSE:NOVO B) has filed a federal lawsuit against Eli Lilly over alleged false and misleading advertising of GLP-1 obesity and diabetes drugs. The company argues that Eli Lilly’s ads misrepresent clinical comparisons and risk misleading consumers and healthcare professionals. The case highlights rising tensions as both companies compete in the fast growing market for GLP-1 based obesity and diabetes treatments. Novo Nordisk is a major player in diabetes and obesity treatments,...

European stock markets closed higher in Friday trading as the eurozone private sector expanded in Ju

(Updates with responses from Novo Nordisk and Eli Lilly in the fourth and fifth paragraphs.) Novo

Novo Nordisk (CPSE:NOVO B) is back in focus after the European Commission granted marketing authorisation for its once daily Wegovy pill across all EU member states, creating a new oral option in GLP 1 obesity treatment. See our latest analysis for Novo Nordisk. The Wegovy pill approval lands at a time when Novo Nordisk’s 90 day share price return of 23.22% suggests momentum is still building, even as the year to date share price return is down 3.01% and the 1 year total shareholder return...

European equities traded in the US as American depositary receipts were tracking higher late Friday

Novo Nordisk, the maker of Ozempic, is suing Eli Lilly over advertisements comparing some of their biggest-selling drugs. The ads compare Lilly’s Zepbound with Novo’s Wegovy, and Novo argues they give consumers a misleading picture of how the blockbuster weight-loss drugs stack up. At the center of ...

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2%, and the actively tra

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

The Danish drugmaker alleges Lilly's advertising misrepresents comparisons between rival obesity treatments.

Novo says Lilly's ads for Zepbound and Mounjaro rely on outdated data and omit newer, higher-dose versions of Wegovy and Ozempic

Friday’s preliminary injunction request escalates legal proceedings initiated earlier this week.

Novo Nordisk is seeking a preliminary U.S. court injunction to immediately block Lilly’s advertisements for Zepbound and Mounjaro, according to a Reuters report on Friday.

Novo Nordisk (NYSE:NVO) has asked a U. S.

Novo Nordisk said it asked a U.S. court to preliminarily halt rival Eli Lilly from advertising weight-loss drugs, days after accusing the Indianapolis drugmaker of using deceptive advertising to mislead consumers in a lawsuit. Friday’s preliminary injunction request, filed in the District of New Jersey, escalates legal proceedings initiated earlier this week. Novo has now asked the court to stop Eli Lilly from advertising its GLP-1 drugs while the lawsuit proceeds.

Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

A 35-year-old institutional powerhouse just made its first move into the ETF market, betting that quality stock picking in developed markets abroad can justify a fee 23 times higher than its cheapest rival.

RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Two more Phase 3 trials showed weight loss above 20%

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical data and unfair dose comparisons to claim superiority over Novo’s Wegovy and Ozempic. The case raises legal and regulatory questions around drug marketing practices in the high-stakes GLP-1 market, where only a few companies currently compete at scale. Beyond the courtroom, this dispute highlights...

LLY's blockbuster GLP-1 portfolio takes center stage as investors watch Mounjaro, Zepbound and Foundayo for clues to Q2 growth and outlook.

Retatrutide, a once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, met the primary endpoint in both the Triumph-2 and Triumph-3 Phase 3 studies.